Drug Search Results
More Filters [+]

Cediranib

Alternative Names: cediranib, recentin, azd2171
Latest Update: 2024-11-13
Latest Update Note: Clinical Trial Update

Product Description

Cediranib is a potent small molecule vascular endothelial growth factor (VEGF) receptor tyrosine kinase (RTK) inhibitor of all three VEGF receptors (VEGFR-1, 2 and 3) at nanomolar concentrations.  (Sourced from: https://nciformulary.cancer.gov/available_agents/Cediranib.htm)

Mechanisms of Action: VEGFR Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Cediranib

Countries in Clinic: Canada, Puerto Rico, United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 2: Clear Cell Adenocarcinoma|Endometrial Cancer|Endometrioid Carcinoma|Mucinous Adenocarcinoma|Mucinous Cystadenocarcinoma|Ovarian Cancer|Peritoneal Cancer|Serous Cystadenocarcinoma|Transitional Cell Carcinoma|Uterine Cancer|Uveal Melanoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCI-2017-01672

P2

Active, not recruiting

Uterine Cancer|Endometrioid Carcinoma|Endometrial Cancer|Serous Cystadenocarcinoma

2024-12-31

CEDUVEAL-M

P2

Active, not recruiting

Uveal Melanoma

2023-03-02

NCI-2021-00615

P2

Active, not recruiting

Mucinous Adenocarcinoma|Ovarian Cancer|Endometrioid Carcinoma|Mucinous Cystadenocarcinoma|Clear Cell Adenocarcinoma|Peritoneal Cancer|Serous Cystadenocarcinoma|Transitional Cell Carcinoma

2023-01-26

Recent News Events